In Brief: Visx/Summit Technology
This article was originally published in The Gray Sheet
Executive Summary
Visx/Summit Technology: Joint venture Pillar Point Partners, formed in 1992 to license Summit and Visx' excimer laser technology, appoints Robert Dougherty its first president and CEO, effective March 24. Dougherty most recently served as VP-advocacy for the American Academy of Ophthalmology...
You may also be interested in...
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.